If you've followed pancreatic cancer news over the years, you know it usually isn’t good. This cancer has one of the worst survival rates of any cancer out there. Because most people are diagnosed when it's already spread, the five-year survival rate sits at a brutal 5% or so globally.
So when researchers announced that a drug called daraxonrasib essentially doubled survival time in pancreatic cancer patients, it genuinely stopped the oncology world in its tracks.
The cards are stacked against patients from the start. About 80% of pancreatic cancers aren't found until they're in advanced stages, which means surgery is already off the table. And even when tumors are caught early and removed, the cancer comes back in up to 80% of patients.
The bleak average life expectancy after diagnosis? About 12 months.
The reason treatment has been so limited for so long comes down to one stubborn genetic villain, a mutation called KRAS. It drives roughly 90% of all pancreatic cancers, and for decades, scientists considered it essentially "undruggable." There just hasn’t been a way to get a drug to latch onto it and block it.
That's finally changing.
Enter Daraxonrasib.
It’s a “targeted therapy” taken as a once-daily oral pill that directly blocks the KRAS mutation driving the cancer. Results from an early-phase clinical trial were presented in April 2026 at the American Association for Cancer Research Annual Meeting, and the numbers turned heads.
Out of 38 patients treated:
-
47% saw their tumors respond positively to the drug
-
71% had no cancer progression at the six-month mark
-
83% were still alive at six months
Compare that to the historical baseline where roughly only 10% of patients survive even one year after a distant-stage diagnosis, and you start to understand why oncologists are excited.
Here's something that often gets lost in survival statistics…
Quality of life matters. Profoundly.
Chemotherapy, while life-extending, comes with brutal side effects like fatigue, nausea, and immune suppression. Since Daraxonrasib is a targeted oral therapy rather than traditional chemo, it showed a meaningful improvement in patients' quality of life in the trial.
This is especially significant for older patients or those with other health conditions who often can't tolerate chemotherapy at all. A drug like this could open treatment doors that were previously shut.
Daraxonrasib isn't the only reason for cautious optimism right now. Researchers are also working on:
-
Combination therapies to overcome the drug resistance that often develops after initially successful KRAS-targeted treatment
-
Immunotherapy approaches specifically designed to break through the protective cellular "barrier" that pancreatic tumors create around themselves — a barrier that's traditionally made immunotherapy useless against this cancer mdanderson.org
Larger Phase 3 trials comparing daraxonrasib directly to standard chemotherapy are already underway, including this high-profile RASolute 302 trial.
To be abundantly clear — this is not a cure.
The trial was small (38 patients), and early-phase results need to hold up in larger studies. Pancreatic cancer is still one of the most lethal diagnoses a person can receive.
But in a disease where progress has been agonizingly slow for three decades, a drug that doubles survival time and does it with fewer side effects than chemotherapy is genuinely historic. As Dr. Wungki Park at MSK put it, "This could be a paradigm shift in how we treat pancreatic cancer after more than three decades of relying mainly on chemotherapy."
For patients and families navigating this diagnosis, that's not nothing.
It’s everything.
Sources:
link.springer.com/article/10.1186/s12885-025-13597-z
bbc.com/news/articles/cy82l435171o
scienceinsights.org/how-severe-is-pancreatic-cancer-stages-and-prognosis/
scienceinsights.org/what-is-a-kras-mutation-and-how-does-it-drive-cancer/
cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy.html
nature.com/articles/s41598-025-12725-w
mdanderson.org/cancerwise/3-recent-advances-in-pancreatic-cancer-research.h00-159780390.html
